Photodynamic therapy of subfoveal recurrences after laser photocoagulation of extrafoveal XXXX in pathologic @entity1714 .

@entity1 @entity4936 @entity1940 @entity471 @entity941 @entity1714 @entity20240
BACKGROUND: Photodynamic therapy with @entity4936 (Visudyne; Novartis, B  lach, Switzerland) has been proposed for the treatment of subfoveal @entity1940 secondary to pathologic @entity1714 . We retrospectively evaluated the effects of @entity4936 therapy of subfoveal recurrences of extrafoveal myopic @entity471 previously treated with thermal laser photocoagulation. METHODS: Twelve eyes, previously treated with thermal laser photocoagulation for extrafoveal @entity1940 , received photodynamic therapy with @entity4936 for subfoveal recurrence of choroidal new vessels. Thirteen eyes that did not receive photodynamic therapy served as control group. Vision and @entity941 angiography outcomes were analyzed on all study visits (every 3 months) through month 12. Visual acuity was measured in Snellen lines. RESULTS: On average, at the month 12 examination the @entity4936 -treated group had gained 2 lines and the untreated group had @entity20240 line of vision. Eleven eyes of the @entity4936 -treated group compared with nine eyes of the untreated group lost fewer than 3 lines of vision, including four eyes versus none improving at least 1 line of vision. CONCLUSION: Photodynamic therapy with @entity4936 might increase the chance of stabilizing or improving vision in @entity1 with subfoveal recurrences of extrafoveal myopic @entity471 previously treated with thermal laser photocoagulation. A prospective, randomized study on larger series of @entity1 is mandatory.
